Novel chemosensitive single-nucleotide polymorphism markers to targeted regimens in metastatic colorectal cancer

Clinical Cancer Research

Volumn 17, Issue 5, 2011, Pages 1200-1209

  Kim, Jin C ^a,b   Kim, Seon Y ^b,c   Cho, Dong H ^b   Ha, Ye J ^b   Choi, Eun Y ^b   Kim, Chan W ^a,b   Roh, Seon A ^a,b   Kim, Tae W ^a,b   Ju, Hyoungseok ^c   Kim, Yong S ^b,c  

^a University of Ulsan College of Medicine   (South Korea)

^b Asan Institute for Life Sciences   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CELL PROTEIN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PROTEIN ANXA11; PROTEIN DFNB31; PROTEIN ISX; PROTEIN LIFR; PROTEIN LINS1; PROTEIN MDM1; PROTEIN SEMA4B; PROTEIN TNC; PROTEIN UTRN; UNCLASSIFIED DRUG;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CELL CULTURE; CANCER SURVIVAL; CELL STRAIN HCT116; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; GENETIC ASSOCIATION; GENETIC TRANSFECTION; GENOME ANALYSIS; GENOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79952267262     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1907     Document Type: Article

References (30)

1. Kelly C, Cassidy J. Chemotherapy in metastatic colorectal cancer. Surg Oncol 2007;16:65-70. (Pubitemid 46880340)
2. Köhne CH, Lenz HJ. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist 2009;14: 478-88.
3. Okines A, Cunningham D. Current perspective: bevacizumab in colorectal cancer - a time for reappraisal? Eur J Cancer 2009;45: 2452-61.
4. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth. Factor receptor-targeted therapy in metastatic clorectal cancer. J Natl Cancer Inst 2009;101:1308-24.
5. Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009;27:5068-74.
6. Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009;15:3184-8.
7. Henriette Tanja L, Guchelaar HJ, Gelderblom H. Pharmacogenetics in chemotherapy of colorectal cancer. Best Pract Res Clin Gastroenterol 2009;23:257-73.
8. Zhang W, Dolan ME. Use of cell lines in the investigation of pharmacogenetic loci. Curr Pharm Des 2009;15:3782-95.
9. Motsinger AA, Ritchie MD, Dobrin SE. Clinical applications of whole-genome association studies: future applications at the bedside. Expert Rev Mol Diagn 2006;6:551-65. (Pubitemid 44179941)
10. Huang RS, Duan S, Shukla SJ, Kistner EO, Clark TA, Chen TX, et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet 2007;81:427-37. (Pubitemid 47330203)
11. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23. (Pubitemid 44450469)
12. Kim JC, Shin ES, Kim CW, Roh SA, Cho DH, Na YS, et al. In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer. Anticancer Res 2009;29:3027-34.
13. Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern PH, Hoffman RM, et al. In vivo-like drug responses of human tumors growing in three-dimensional gel supported primary culture. Proc Natl Acad Sci U S A 1987;84:5029-33.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000;92:205-16. (Pubitemid 30099779)
15. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007;96:1166-9. (Pubitemid 46625066)
16. Ge D, Zhang K, Need AC, Martin O, Fellay J, Urban TJ, et al. WGAViewer: software for genomic annotation of whole genome association studies. Genome Res 2008;18:640-3. (Pubitemid 351482788)
17. Braun MS, Quirke P, Seymour MT. Molecular markers of chemotherapeutic response and toxicity in colorectal cancer. Expert Rev Anticancer Ther 2007;7:489-501. (Pubitemid 46681805)
18. Li L, Fridley BL, Kalari K, Jenkins G, Batzler A, Weinshilboum RM, et al. Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS One 2009;4: e7765.
19. Sargent JM. The use of the MTT assay to study drug resistance in fresh tumour samples. Recent Results Cancer Res 2003;161:13-25.
20. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008;9:356-69. (Pubitemid 351556063)
21. Krawczak M, Thomas NS, Hundrieser B, Mort M, Wittig M, Hampe J, et al. Single base-pair substitutions in exon-intron junctions of human genes: nature, distribution, and consequences for mRNA splicing. Hum Mutat 2007;28:150-8. (Pubitemid 46233312)
22. Wang J, Shete S. A test for genetic association that incorporates information about deviation from Hardy-Weinberg proportions in cases. Am J Hum Genet 2008;83:53-63.
23. Fox R, Aubert M. Flow cytometric detection of activated caspase-3. Methods Mol Biol 2008;414:47-56.
24. Rockman SP, Demmler K, Roczo N, Cosgriff A, Phillips WA, Thomas RJ, et al. Expression of interleukin-6, leukemia inhibitory factor and their receptors by colonic epithelium and pericryptal fibroblasts. J Gastroenterol Hepatol 2001;16:991-1000. (Pubitemid 32947141)
25. Kamohara H, Sakamoto K, Ishiko T, Masuda Y, Abe T, Ogawa M. Leukemia inhibitory factor induces apoptosis and proliferation of human carcinoma cells through different oncogene pathways. Int J Cancer 1997;72:687-95. (Pubitemid 27356173)
26. de la Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ, et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 2008;22:449-62. (Pubitemid 351272753)
27. Lobo GP, Hessel S, Eichinger A, Noy N, Moise AR, Wyss A, et al. ISX is a retinoic acid-sensitive gatekeeper that controls intestinal beta,beta-carotene absorption and vitamin A production. FASEB J 2010;24: 1656-66.
28. Baynes RD, Gansert J. KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer. Am J Ther 2009;16:554-61.
29. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
30. Hofmann S, Franke A, Fischer A, Jacobs G, Nothnagel M, Gaede KI, et al. Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis. Nat Genet 2008;40:1103-6.